Sulzer Medica confident with new $1 billion implants plan
This article was originally published in Clinica
Executive Summary
Sulzer Medica may be a mere few months away from settling the faulty Inter-Op hip implant saga that dogged it for all of last year and caused its share price to crumple to a fraction of its value before the event. The Swiss company has formed a new $1 billion proposed settlement after negotiations that included the plaintiffs' lawyers. Shares in the company leapt by over 20% to around SFr110 ($65) on the disclosure.